Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note released on Tuesday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Down 3.7 %

Shares of Eagle Pharmaceuticals stock opened at $5.76 on Tuesday. Eagle Pharmaceuticals has a 12-month low of $3.21 and a 12-month high of $23.52. The stock has a market cap of $74.81 million, a P/E ratio of 4.88 and a beta of 0.51. The business’s 50 day moving average is $4.56 and its 200-day moving average is $4.99.

Institutional Investors Weigh In On Eagle Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in EGRX. Los Angeles Capital Management LLC raised its stake in shares of Eagle Pharmaceuticals by 110.1% during the 1st quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock worth $1,005,000 after purchasing an additional 100,470 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Eagle Pharmaceuticals by 378.7% during the 4th quarter. BNP Paribas Financial Markets now owns 88,685 shares of the specialty pharmaceutical company’s stock worth $464,000 after purchasing an additional 70,158 shares in the last quarter. Trexquant Investment LP raised its stake in shares of Eagle Pharmaceuticals by 88.0% during the 4th quarter. Trexquant Investment LP now owns 126,282 shares of the specialty pharmaceutical company’s stock worth $660,000 after purchasing an additional 59,095 shares in the last quarter. DGS Capital Management LLC raised its stake in shares of Eagle Pharmaceuticals by 442.5% during the 1st quarter. DGS Capital Management LLC now owns 61,944 shares of the specialty pharmaceutical company’s stock worth $325,000 after purchasing an additional 50,525 shares in the last quarter. Finally, Jump Financial LLC raised its stake in Eagle Pharmaceuticals by 172.0% in the 4th quarter. Jump Financial LLC now owns 38,900 shares of the specialty pharmaceutical company’s stock valued at $203,000 after acquiring an additional 24,600 shares during the period. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.